Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review
Paediatr Drugs. 2023 Jun 15. doi: 10.1007/s40272-023-00579-6. Online ahead of print.ABSTRACTInflammatory bowel disease (IBD) is a chronic systemic immune-mediated disorder. The disease is triggered and perpetuated by a complex interplay between genetic predisposition, dysregulated immune responses, and environmental factors. Pediatric IBD is considered to be more aggressive compared with adult-onset IBD, and commonly requires more intensive pharmacological and surgical treatments. Although the use of targeted therapy, such as biologic therapy and small molecule therapy, is on the rise, there are children with IBD who are r...
Source: Paediatric Drugs - June 15, 2023 Category: Pediatrics Authors: Anat Yerushalmy-Feler Caroline Brauner Shlomi Cohen Source Type: research
Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review
Paediatr Drugs. 2023 Jun 15. doi: 10.1007/s40272-023-00579-6. Online ahead of print.ABSTRACTInflammatory bowel disease (IBD) is a chronic systemic immune-mediated disorder. The disease is triggered and perpetuated by a complex interplay between genetic predisposition, dysregulated immune responses, and environmental factors. Pediatric IBD is considered to be more aggressive compared with adult-onset IBD, and commonly requires more intensive pharmacological and surgical treatments. Although the use of targeted therapy, such as biologic therapy and small molecule therapy, is on the rise, there are children with IBD who are r...
Source: Paediatric Drugs - June 15, 2023 Category: Pediatrics Authors: Anat Yerushalmy-Feler Caroline Brauner Shlomi Cohen Source Type: research
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age
CONCLUSIONS: The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1-6 months of age are comparable to those in children older than 6 months of age.TRIAL REGISTRATION: Clinicaltrials.gov Trial Registration number and date: NCT02583399-Registered July 2017.PMID:37294477 | DOI:10.1007/s40272-023-00576-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 9, 2023 Category: Pediatrics Authors: Chris D Glover John W Berkenbosch Mary B Taylor Nihar V Patel Byron Kaelin Breanne H Y Gibson John Zhong Source Type: research
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age
CONCLUSIONS: The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1-6 months of age are comparable to those in children older than 6 months of age.TRIAL REGISTRATION: Clinicaltrials.gov Trial Registration number and date: NCT02583399-Registered July 2017.PMID:37294477 | DOI:10.1007/s40272-023-00576-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 9, 2023 Category: Pediatrics Authors: Chris D Glover John W Berkenbosch Mary B Taylor Nihar V Patel Byron Kaelin Breanne H Y Gibson John Zhong Source Type: research
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age
CONCLUSIONS: The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1-6 months of age are comparable to those in children older than 6 months of age.TRIAL REGISTRATION: Clinicaltrials.gov Trial Registration number and date: NCT02583399-Registered July 2017.PMID:37294477 | DOI:10.1007/s40272-023-00576-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 9, 2023 Category: Pediatrics Authors: Chris D Glover John W Berkenbosch Mary B Taylor Nihar V Patel Byron Kaelin Breanne H Y Gibson John Zhong Source Type: research
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age
CONCLUSIONS: The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1-6 months of age are comparable to those in children older than 6 months of age.TRIAL REGISTRATION: Clinicaltrials.gov Trial Registration number and date: NCT02583399-Registered July 2017.PMID:37294477 | DOI:10.1007/s40272-023-00576-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 9, 2023 Category: Pediatrics Authors: Chris D Glover John W Berkenbosch Mary B Taylor Nihar V Patel Byron Kaelin Breanne H Y Gibson John Zhong Source Type: research
A Multi-Center Evaluation of the Pharmacokinetics and Safety of Intravenous Ibuprofen in Infants 1-6 Months of Age
CONCLUSIONS: The pharmacokinetic and short-term safety profiles of IV ibuprofen in pediatric patients 1-6 months of age are comparable to those in children older than 6 months of age.TRIAL REGISTRATION: Clinicaltrials.gov Trial Registration number and date: NCT02583399-Registered July 2017.PMID:37294477 | DOI:10.1007/s40272-023-00576-9 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 9, 2023 Category: Pediatrics Authors: Chris D Glover John W Berkenbosch Mary B Taylor Nihar V Patel Byron Kaelin Breanne H Y Gibson John Zhong Source Type: research
Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature
CONCLUSION: Given its effectiveness and safety, ruxolitinib could be used to treat SR-GVHD in children after HSCT.PMID:37284944 | DOI:10.1007/s40272-023-00577-8 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 7, 2023 Category: Pediatrics Authors: Wei-Ling Yan Fen-Ying Zhao Min-Er Gu Nan Liu Xiao-Ping Guo Xiao-Jun Xu Source Type: research
Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature
CONCLUSION: Given its effectiveness and safety, ruxolitinib could be used to treat SR-GVHD in children after HSCT.PMID:37284944 | DOI:10.1007/s40272-023-00577-8 (Source: Paediatric Drugs)
Source: Paediatric Drugs - June 7, 2023 Category: Pediatrics Authors: Wei-Ling Yan Fen-Ying Zhao Min-Er Gu Nan Liu Xiao-Ping Guo Xiao-Jun Xu Source Type: research
Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center
CONCLUSION: Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.PMID:37269500 | DOI:10...
Source: Paediatric Drugs - June 3, 2023 Category: Pediatrics Authors: Sulaima Albinni Julian Heno Imre Pavo Erwin Kitzmueller Manfred Marx Ina Michel-Behnke Source Type: research
Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center
CONCLUSION: Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.PMID:37269500 | DOI:10...
Source: Paediatric Drugs - June 3, 2023 Category: Pediatrics Authors: Sulaima Albinni Julian Heno Imre Pavo Erwin Kitzmueller Manfred Marx Ina Michel-Behnke Source Type: research
Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center
CONCLUSION: Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.PMID:37269500 | DOI:10...
Source: Paediatric Drugs - June 3, 2023 Category: Pediatrics Authors: Sulaima Albinni Julian Heno Imre Pavo Erwin Kitzmueller Manfred Marx Ina Michel-Behnke Source Type: research
Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center
CONCLUSION: Data presented herein account for the largest cohort of severely affected pediatric patients receiving macitentan. Overall, macitentan was safe and associated with significant beneficial effects and sustained positive signals after 1 year, albeit in the long term disease progression remains a major concern. Our data suggest limited efficacy in CHD-related PH, whereas favorable outcomes were mainly driven by improvements in patients with PH not related to CHD. Larger studies are needed to verify these preliminary results and to prove efficacy of this drug in different pediatric PH entities.PMID:37269500 | DOI:10...
Source: Paediatric Drugs - June 3, 2023 Category: Pediatrics Authors: Sulaima Albinni Julian Heno Imre Pavo Erwin Kitzmueller Manfred Marx Ina Michel-Behnke Source Type: research
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury
Paediatr Drugs. 2023 Jun 2. doi: 10.1007/s40272-023-00572-z. Online ahead of print.ABSTRACTAcute kidney injury (AKI) is a commonly encountered comorbidity in critically ill children. The coexistence of AKI disturbs drug pharmacokinetics and pharmacodynamics, leading to clinically significant consequences. This can complicate an already critical clinical scenario by causing potential underdosing or overdosing giving way to possible therapeutic failures and adverse reactions. Current available studies offer little guidance to help maneuver such complex dosing regimens and decision-making in pediatric patients as most of them...
Source: Paediatric Drugs - June 2, 2023 Category: Pediatrics Authors: Manan Raina Amani Ashraf Anvitha Soundararajan Anusree Krishna Mandal Sidharth Kumar Sethi Source Type: research
Pharmacokinetics in Critically Ill Children with Acute Kidney Injury
Paediatr Drugs. 2023 Jun 2. doi: 10.1007/s40272-023-00572-z. Online ahead of print.ABSTRACTAcute kidney injury (AKI) is a commonly encountered comorbidity in critically ill children. The coexistence of AKI disturbs drug pharmacokinetics and pharmacodynamics, leading to clinically significant consequences. This can complicate an already critical clinical scenario by causing potential underdosing or overdosing giving way to possible therapeutic failures and adverse reactions. Current available studies offer little guidance to help maneuver such complex dosing regimens and decision-making in pediatric patients as most of them...
Source: Paediatric Drugs - June 2, 2023 Category: Pediatrics Authors: Manan Raina Amani Ashraf Anvitha Soundararajan Anusree Krishna Mandal Sidharth Kumar Sethi Source Type: research
